Laserfiche WebLink
Plan Financials <br /> Executive Summary: Calendar YTD through December <br /> Historical Costs <br /> Plan Cost History <br /> YTD through December <br /> January 2020 thru January 2019 thru <br /> December 2020 December 2019 <br /> Avera'e Enrollment 1 677 1 664 <br /> Com•onent of Cost Total Current PEPM PEPM <br /> Medical Rx Administration 1 136 458 5611111110111111111 <br /> Sta. Loss Premium •.894 241 •.44 .34 <br /> Medical Claims Net of ISL ••14 180 794 •.705 •.704 <br /> Rx Claims less Rx Rebates •.4 047 052 •.201 •.246 <br /> Total 20 258 544 1 007 1 036 <br /> Year-over-Year Trend -2.8% N A <br /> Trend History <br /> YTD through December <br /> January 2020 thru <br /> December 2020 <br /> Com•onent of Cost Total Current Trend <br /> Medical Rx Administration •.1 136 458 9.4% <br /> Sto• Loss Premium •4394 241 30.7% <br /> Medical Claims Net of ISL •.14 180 794 0.1% <br /> Rx Claims less Rx Rebates .4 047 052 -18.4% <br /> Total 20 258 544 -2.8% <br /> Trend <br /> For the period January 2020 through December 2020, the plan is trending -2.8%. Significant <br /> reduction in the pharmacy spend has been realized from the prior 12-month period. <br /> Primary Cost Drivers: <br /> 1.9%of members account for 45%of plan spend <br /> High-cost claimants are members who have claims in excess of$50,000 <br /> Utilization patterns: <br /> Inpatient Admissions- 21%of total cost; (17%decrease from year prior) <br /> Emergency Room -6%of total costs (8% increase over year prior) <br /> The most costly conditions by spend: <br /> Multiple Sclerosis, Ulcerative Colitis/Crohn's, Breast and Gynecological Cancers, End <br /> Stage Renal Disease <br /> 3 <br />